Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.
Also called NCT03767543
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 265 participants
- Sponsor
- Registry
-
NCT03767543
-
- Other papers using this trial's data
- Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03767543. Randomized; no masking; primary purpose treatment. Start 2019-03-11 (actual); primary completion 2020-10-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
- Acronym
- LixilanOne CAN
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03767543- Content hash
e1b90688aacc4151d250290b109e8629cdd219c583d573f93309251c1965006f